A cross-sectional study of nurses explored the mediating factors behind their attitudes toward seeking psychological help.
Both regimens “can be considered standard chemotherapy options” for high-risk, HR-positive early breast cancer, said Sherko Kuemmel, MD, PhD.
NP-101 plus nivolumab and ipilimumab demonstrated activity in patients with metastatic EP-NECs that were refractory to chemotherapy.
Similar findings with no significant association seen when accounting for hormone therapy status and duration of use.